{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:22:14Z","timestamp":1761196934679,"version":"3.40.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Aims:&lt;\/i&gt; To investigate the safety and tolerability of pardoprunox (SLV308), a novel partial dopamine agonist, as an adjunct to levodopa in patients with advanced Parkinson\u2019s disease, using two titration schedules. &lt;i&gt;Methods:&lt;\/i&gt; Patients were randomized to pardoprunox (n = 51) or placebo (n = 11). Pardoprunox was titrated to the highest tolerated dose (range, 0.3\u201342 mg\/day) over 7 weeks, using a gradual dose escalation without intermediate steps (group 1) or with intermediate steps (group 2). &lt;i&gt;Results:&lt;\/i&gt; The cumulative drop-out rate was greater in group 1 (without intermediate steps, 56.0%) than in group 2 (with intermediate steps, 34.6%), or with placebo (9.1%). In group 2, doses up to 18 mg\/day were well tolerated with a cumulative drop-out rate of 7.7% (2\/26) and a drop-out rate due to adverse events of 4.0% (1\/26). The most common adverse events reported were nausea, vomiting, headache, and dizziness. There was a trend for reduced OFF time (p = 0.054) in the combined pardoprunox group compared to placebo. &lt;i&gt;Conclusions:&lt;\/i&gt; The pardoprunox safety and tolerability profile as an adjunct to levodopa was improved using a gradual titration schedule that included intermediate dose steps. Using this titration, doses up to 18 mg\/day were well tolerated.<\/jats:p>","DOI":"10.1159\/000216839","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T14:05:34Z","timestamp":1241013934000},"page":"40-48","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson\u2019s Disease"],"prefix":"10.1159","volume":"62","author":[{"given":"R.A.","family":"Hauser","sequence":"first","affiliation":[]},{"given":"J.","family":"Bronzova","sequence":"additional","affiliation":[]},{"given":"C.","family":"Sampaio","sequence":"additional","affiliation":[]},{"given":"A.E.","family":"Lang","sequence":"additional","affiliation":[]},{"given":"O.","family":"Rascol","sequence":"additional","affiliation":[]},{"given":"A.","family":"Theeuwes","sequence":"additional","affiliation":[]},{"given":"S.V.","family":"van de Witte","sequence":"additional","affiliation":[]}],"member":"127","published-online":{"date-parts":[[2009,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002%2Fana.10513"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS1471-1931%2800%2900030-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000137111"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097%2F00002826-200003000-00003"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002%2Fmds.20397"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000259516.61938.bb"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS1474-4422%2807%2970108-4"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:13:35Z","timestamp":1745446415000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000216839","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"type":"print","value":"0014-3022"},{"type":"electronic","value":"1421-9913"}],"subject":[],"published":{"date-parts":[[2009]]}}}